Evidence-Based Cardiovascular Disease Medicines' Availability in Low-Cost Generic Drug Programs in the United States : A Cross-Sectional Study
Authors' conclusion
Coverage of evidence-based medications for the 6 CVDs investigated varied by LCGP and condition.
Study context
- Population
- Publicly available low-cost generic drug programs (low-cost generic programs (LCGPs)) in the US, March and April 2023
- Participants
- 19 LCGPs
- Outcome
- Proportion of LCGPs offering evidence-based CVD medicines for 6 CVDs (AF, HF, hyperlipidemia, hypertension, post-ACS secondary prevention, stable angina) by 4 availability metrics (breadth, choice, high-quality evidence, titratability)
Methodological detailsIn-depth cost analysis not investigated
- In-depth cost analysis not investigated
Main finding
As reported in the abstract
- Cardiovascular disease (CVD) medication availability varied by program, drug and CVD condition
- More breadth and choice of coverage for most CVDs: H-E-B, Kroger, Mark Cuban Cost Plus Drug Company, Walmart; many others more focused or markedly limited
- Nearly all LCGPs offered ACEi, β-blockers, thiazides and moderate-intensity statins
- Low availability of higher-cost or lower-use generics (antiplatelets, antiarrhythmics)
- Core pharmacotherapy coverage and choices limited for AF and HF, widely available for hypertension and hyperlipidemia
Observational data: associations, not effects.
Original publication
Evidence-Based Cardiovascular Disease Medicines' Availability in Low-Cost Generic Drug Programs in the United States : A Cross-Sectional Study. Ann Intern Med. Published 5 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →